These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 2412489)

  • 41. Biological activity of an intravenous preparation of human vaccinia immune globulin in mouse models of vaccinia virus infection.
    Shearer JD; Siemann L; Gerkovich M; House RV
    Antimicrob Agents Chemother; 2005 Jul; 49(7):2634-41. PubMed ID: 15980330
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Use of interleukin-2 and macrophages to treat herpes simplex virus infection in neonatal mice.
    Kohl S; Loo LS
    J Infect Dis; 1988 Jun; 157(6):1187-92. PubMed ID: 2836520
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Neuroendocrine hormones suppress macrophage-mediated lysis of herpes simplex virus-infected cells.
    Koff WC; Dunegan MA
    J Immunol; 1986 Jan; 136(2):705-9. PubMed ID: 3001183
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Protection of mice against vaccinia and herpes simplex virus infection by Propionibacterium acnes.
    Zgórniak-Nowosielska I; Cwik D; Sławińska B
    Arch Immunol Ther Exp (Warsz); 1989; 37(3-4):431-42. PubMed ID: 2639640
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Differential effects of the type I interferons alpha4, beta, and epsilon on antiviral activity and vaccine efficacy.
    Day SL; Ramshaw IA; Ramsay AJ; Ranasinghe C
    J Immunol; 2008 Jun; 180(11):7158-66. PubMed ID: 18490714
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein D prevents latent herpes in mice.
    Cremer KJ; Mackett M; Wohlenberg C; Notkins AL; Moss B
    Science; 1985 May; 228(4700):737-40. PubMed ID: 2986288
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Poly I:C-induced anti-herpes simplex virus type 1 activity in inflammatory macrophages is mediated by induction of interferon-beta.
    Pyo S; Gangemi JD; Ghaffar A; Mayer EP
    J Leukoc Biol; 1991 Nov; 50(5):479-87. PubMed ID: 1660913
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The mechanisms of antiviral immunity induced by a vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein D: clearance of local infection.
    Martin S; Rouse BT
    J Immunol; 1987 May; 138(10):3431-7. PubMed ID: 3033075
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Growth hormone improves the resistance of thermally injured mice infected with herpes simplex virus type 1.
    Takagi K; Suzuki F; Barrow RE; Wolf SE; Kobayashi M; Herndon DN
    J Trauma; 1998 Mar; 44(3):517-22. PubMed ID: 9529182
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Protection of neonatal mice against herpes simplex virus infection: probable in vivo antibody-dependent cellular cytotoxicity.
    Kohl S; Loo LS
    J Immunol; 1982 Jul; 129(1):370-6. PubMed ID: 6282968
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Augmentation by priming with interferon-gamma of the binding of a muramyl dipeptide derivative to macrophages resulting in synergistic macrophage activation.
    Nagao S; Sato K; Osada Y
    Jpn J Cancer Res; 1987 Jan; 78(1):80-6. PubMed ID: 3102442
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Stimulation of non-specific resistance to infection by muroctasin.
    Otani T; Une T; Osada Y
    Arzneimittelforschung; 1988 Jul; 38(7A):969-76. PubMed ID: 3056426
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Experimental infection of inbred mice with herpes simplex virus. VI. Effect of interferon on in vitro virus replication in macrophages.
    Brücher J; Domke I; Schröder CH; Kirchner H
    Arch Virol; 1984; 82(1-2):83-93. PubMed ID: 6208880
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effect of IL-6 deficiency on susceptibility to HSV-1 respiratory infection and intrinsic macrophage antiviral resistance.
    Murphy EA; Davis JM; Brown AS; Carmichael MD; Ghaffar A; Mayer EP
    J Interferon Cytokine Res; 2008 Oct; 28(10):589-95. PubMed ID: 18778200
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Evaluation of antiviral immunity using vaccinia virus recombinants expressing cloned genes for herpes simplex virus type 1 glycoproteins.
    Martin S; Cantin E; Rouse BT
    J Gen Virol; 1989 Jun; 70 ( Pt 6)():1359-70. PubMed ID: 2543783
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Distinct patterns of IFN sensitivity observed in cells infected with vaccinia K3L- and E3L- mutant viruses.
    Beattie E; Paoletti E; Tartaglia J
    Virology; 1995 Jul; 210(2):254-63. PubMed ID: 7542414
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The antiviral activity of 9-beta-D-arabinofuranosyladenine is enhanced by the 2',3'-dideoxyriboside, the 2',3'-didehydro-2',3'-dideoxyriboside and the 3'-azido-2',3'-dideoxyriboside of 2,6-diaminopurine.
    Balzarini J; De Clercq E
    Biochem Biophys Res Commun; 1989 Feb; 159(1):61-7. PubMed ID: 2538128
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effect of macrophage activation on resistance of mouse peritoneal macrophages to infection with herpes simplex virus types 1 and 2.
    Sit MF; Tenney DJ; Rothstein JL; Morahan PS
    J Gen Virol; 1988 Aug; 69 ( Pt 8)():1999-2010. PubMed ID: 2841412
    [TBL] [Abstract][Full Text] [Related]  

  • 59. In vivo significance of NK cell on resistance against virus (HSV-1) infections in mice.
    Habu S; Akamatsu K; Tamaoki N; Okumura K
    J Immunol; 1984 Nov; 133(5):2743-7. PubMed ID: 6207244
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Activity of the Keggin polyoxotungstate PM-19 against herpes simplex virus type 2 infection in immunosuppressed mice: role of peritoneal macrophage activation.
    Ikeda S; Nishiya S; Yamamoto A; Yamase T; Nishimura C; De Clercq E
    J Med Virol; 1993 Nov; 41(3):191-5. PubMed ID: 8263499
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.